OMBP News Alert Omni Bio Pharm Inc (OMBP) 0.2100 09/28/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Omni Bio Pharm Inc (OMBP) 0.2100 $OMBP

Omni Bio to Present at 7th Annual BioPharm America Conference
Marketwire - Tue Sep 16, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio" , an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today that it will present at the 7th Annual BioPharm America(TM) 2014 conference, September 22-24, held at the Boston Marriott Copley Place in Boston, MA.

Omni Bio Appoints Jack Riccardi as Chief Financial Officer
Marketwire - Thu Aug 14, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio" , an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the appointment of Jack Riccardi as its Chief Financial Officer. Mr. Riccardi brings more than 30 years of financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi's appointment will become effective on September 1, 2014.

Omni Bio Pharmaceutical Inc appoints Sandra J. Wrobel to board
M2 - Thu Jul 18, 6:31AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical Inc (OTCBB:OMBP) reported on Wednesday the election of Sandra J. Wrobel MBA to its board of directors, with effect from 15 July 2013.

Omni Bio Pharmaceutical Appoints Ms. Sandra Wrobel as New Director
Marketwire - Wed Jul 17, 3:00PM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Ms. Sandra J. Wrobel, MBA, to its Board of Directors, effective July 15, 2013.

Omni Bio Announces Support for Clinical Trial of Graft vs Host Disease
Marketwire - Wed Jul 10, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced its financial support for a clinical trial of AAT for the treatment of complications following bone marrow transplantation, commonly referred to as Graft versus Host Disease ("GvHD" .

Omni Bio Announces First Results for Its Lead Recombinant Molecule
Marketwire - Fri Mar 15, 7:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced the first disclosure of important results for its recombinant molecule, Fc-AAT.

Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director
Marketwire - Wed Feb 06, 8:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Michael E. Kamarck, Ph.D., to its Board of Directors, effective January 31, 2013.

Omni Bio Pharmaceutical CEO Provides Company Update
Marketwire - Thu Jan 31, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today provided a company update from its new CEO, Dr. Bruce E. Schneider.

Omni Bio Pharmaceutical Appoints New CEO
Marketwire - Thu Dec 20, 7:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr. Schneider will also become a member of the Company's board of directors. In addition to this appointment, Omni Bio announced that it has engaged Bruce D. Forrest, MD, through B D Forrest & Company, Inc., as a consultant in the areas of product and business development. Both Dr. Schneider and Dr. Forrest are former executives at Wyeth, which was acquired by Pfizer in 2009.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Maritime Injury Law: Neidzwski Talks Sea Changes

Updated Category News Views 96

Legal waters are as choppy as the seas themselves, especially in the maritime injury law arena. Nicholas J. Neidzwski, a maritime injury attorney and partner at BoatLaw, LLP, recently waded into these turbulent waters at the 2026 Pacific Admiralty Seminar. This isn’t just any gathering; it’s the West Coast’s legal beacon on all things maritime, drawing in industry...

Continue Reading
InsurGrid's AI Unveils Real-Time Policy Alerts

Updated Category News Views 95

InsurGrid's Latest Tech Fooled No One InsurGrid's fresh off the press news about launching a snazzy AI that flags policy shifts immediately is a bold move. The question you gotta ask yourself is, "Why dig into AI now?" Well, these folks want to make sure insurance agencies aren't left holding outdated policies when everything tanks. Think of it as proactive customer...

Continue Reading
Datavault AI's Turbulent Boardroom Saga Escalates

Updated Category News Views 142

The Corporate Chess Game at Datavault AI If there's one thing Wall Street hates, it's uncertainty. And boy, does Datavault AI (NASDAQ: DVLT) deliver plenty of it right now. Founder Nathaniel Bradley has lobbed a lawsuit at the board, claiming that Chairman and CFO Brett Moyer orchestrated a coup to oust him without proper board procedures. Talk about drama fit for a soap...

Continue Reading
Alley Cat Allies Sues Lincolnton Over Cat Shooting

Updated Category News Views 426

Legal Battle Over a Cat's Tragic End Picture the scene: a peaceful neighborhood in Lincolnton, Georgia, where the serenity was ripped apart by the shocking shooting of Piper the cat. This isn't some playground scuffle, my friends. Alley Cat Allies has taken this tragedy to the courts, filing a lawsuit against the city and its mayor. What's at stake here isn't just legal...

Continue Reading
Delta Dental Expands Free Oral Care Access in NM

Updated Category News Views 160

Bridging Dental Care Gaps in New Mexico When the calendar flips to early November, Delta Dental of New Mexico is joining hands with the NM Mission of Mercy for a no-cost dental clinic at EXPO New Mexico. We're talking doors flying open at 5:15 a.m. sharp, on November 6 and 7. This isn’t some run-of-the-mill thing—they are targeting those who can't easily get or afford...

Continue Reading
Capitol Securities Adds Financial Veterans to Team

Updated Category News Views 153

Big Moves in Sarasota: Capitol Securities' New Additions In a world where every Wall Street whisper can send ripples through financial markets, Capitol Securities Management's move to bring on Joe Malave and Katy Carrigan is anything but a minor footnote. You'd think, by now, we'd be numb to industry shifts, but when a pro like Malave, with his 30 years of financial...

Continue Reading
Louisiana's Musical Legacy Gets a Boost from Foundation

Updated Category News Views 110

Preserving the Tunes of the Bayou Well, if that ain't music to your ears! The Louisiana First Horizon Foundation is sliding into the spotlight with news that's bound to strike a chord with any lover of the state's iconic rhythms. They're diving in deep, backing the Louisiana Music Museum right in the heart of Lafayette. Now, that ain't just another charity stunt; it's a...

Continue Reading
Lifeway Kefir Hits Broadcasters with Football Flair

Updated Category News Views 120

Kefir Goes Prime Time in Chicago Lifeway Foods, Inc. is stepping up its game with a splashy debut on Chicago's television scene. Just days after announcing the move, the leading player in the kefir industry is rolling out an ad campaign featuring none other than celebrated football stars Colston Loveland and D'Andre Swift. This isn't just any run-of-the-mill commercial...

Continue Reading
Interface Faces Sales Outlook Investigation Storm

Updated Category News Views 62

A Shift That Rattled Investors Interface's recent tumble in the market wasn't just a quick slip; it was a full-on somersault. The company's revised sales outlook for 2026 turned out to be a real doozy, firing up the sniffer dogs at SueWallSt into an investigation. If you've been holding onto those NASDAQ:TILE shares, this might just be the type of headache you'd want to...

Continue Reading
Esperto's Space Health Tech Eyes Terrestrial Gains

Updated Category News Views 77

The cosmos isn't just a playground for astronauts. It's a proving ground for the next wave of medical innovation, courtesy of Esperto Medical. They're trotting into uncharted territory with the Translational Research Institute for Space Health (TRISH) grant in hand, determined to transform healthcare both in space and on our own turf. Groundbreaking Tech for Extreme...

Continue Reading

Top 5 Most Recently Viewed Articles

Join Our Insightful Investor Webinar on Upcoming Bond Issues

Updated Category News Views 152

Exploring Opportunities in Renewable Energy Investments Atsinaujinan?ios Energetikos Investicijos is excited to extend an invitation for investors to attend an informative webinar focused on an upcoming bond issue. This event promises to provide valuable insights and information for potential investors interested in renewable energy ventures. Webinar Details You Can't...

Continue Reading
4DMedical Secures Major Funding to Expand Lung Imaging Solutions

Updated Category News Views 175

4DMedical Secures Major Funding for U.S. Expansion 4DMedical, a pioneer in software-based respiratory imaging technology, has achieved a significant milestone by securing over US$100 million in funding. This capital influx aims to exponentially accelerate the adoption of their innovative CT:VQ™ imaging product in the United States. Importance of CT:VQ™ Imaging...

Continue Reading
The Future of Anti-Counterfeit Packaging: Market Analysis

Updated Category News Views 139

Understanding the Anti-Counterfeit Packaging Market In recent years, the anti-counterfeit packaging market has been witnessing significant growth. Analysts project that it will reach an impressive USD 571.77 billion by the year 2034. Notably, the market saw a remarkable expansion from USD 148.73 billion in 2023 to around USD 165.74 billion in 2024. This trajectory implies...

Continue Reading
Ontex's Strategic Shift: Selling Brazilian Operation to Softys

Updated Category News Views 106

Ontex Group NV grabbed attention back in 2024 with its decision to sell off its Brazilian operations to Softys S. A. for a hefty BRL 671 million—around €110 million. This move wasn’t just some casual shuffle; it was a strategic play aimed at reshaping Ontex's portfolio. Why Ontex Sold: Strategic Shift or Desperation? Gustavo Calvo Paz, the CEO of Ontex, was vocal...

Continue Reading
Tesla's Cybercab Tests Bring Excitement Amid Model Y Updates

Updated Category News Views 300

Tesla Inc. Launches New Cybercab Testing Phase Tesla Inc. (NASDAQ: TSLA) is making waves in the electric vehicle sector as testing for its latest innovation, the Cybercab, unfolds at Gigafactory Texas and Fremont, California. This comes at an exciting juncture where the company has just unveiled affordable trims for its popular Model Y and Model 3. Cybercab Sighted at...

Continue Reading